TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its lead approved product is BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Injection for intravenous therapy, indicated for relapsing forms of multiple sclerosis (RMS) in the United States. The company also has additional product candidates in clinical development and relies on third-party manufacturers and licensors for its pipeline.
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-27 | 2025-12-31 | 0001437749-26-006133 | EDGAR | 93K words |
| 2025-03-03 | 2024-12-31 | 0001437749-25-005908 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001437749-24-006144 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001558370-23-002610 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002617 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001558370-21-002149 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001558370-20-001897 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001654954-19-002189 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001654954-18-002638 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001654954-17-002050 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001437749-25-033363 | EDGAR | 67K words |
| 2025-08-08 | 2025-06-30 | 0001437749-25-025745 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001437749-25-015804 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001437749-24-033948 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001437749-24-025853 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001437749-24-014849 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001437749-23-030412 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0001558370-23-013429 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001558370-23-008385 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017180 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001558370-22-012854 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001558370-22-008130 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001437749-26-009253 | EDGAR | 1K words |
| 2026-02-26 | 0001437749-26-005733 | EDGAR | — |
| 2026-01-13 | 0001437749-26-001194 | EDGAR | — |
| 2025-11-03 | 0001437749-25-032658 | EDGAR | — |
| 2025-08-04 | 0001437749-25-024480 | EDGAR | — |
| 2025-06-13 | 0001437749-25-020335 | EDGAR | — |
| 2025-05-05 | 0001437749-25-014402 | EDGAR | — |
| 2025-03-03 | 0001437749-25-005802 | EDGAR | — |
| 2025-01-14 | 0001437749-25-001106 | EDGAR | — |
| 2024-11-04 | 0001437749-24-033055 | EDGAR | — |
373 total filings indexed. 341 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001001316 |
| Ticker | TGTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.tgtherapeutics.com |
| Listed | 1995-12-14 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report